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Abstract
The aim of the study was to establish 12-month changes in the Hammersmith Functional motor scale in a large cohort of SMA patients, to
identify patterns of disease progression and the effect of different variables. 268 patients were included in this multicentric study. Their age ranged
between 2.5 and 55.5 years at baseline, 68 were ambulant and 200 non-ambulant. The baseline scores ranged between 0 and 66 (mean 23.91, SD
20.09). The 12-month change was between −14 and +9 (mean −0.56, SD 2.72). Of the 268 patients, 206 (76.86%) had changes between −2 and
+2 points. Ambulant and non-ambulant subjects had a different relationship between baseline values and age (p for age X ambulation
interaction = 0.007). There was no association with age in ambulant subjects, while there was a significant heterogeneity at different age for
non-ambulant patients (p < 0.001). The 12-month change (adjusted for baseline) was not associated with age in ambulant patients (p = 0.34), but
it was significantly different among various age groups in non-ambulant patients. Our results suggest that there are different profiles of progression
in ambulant and non-ambulant patients, and that age may play an important role in the progression of non-ambulant patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Keywords: Spinal muscular atrophy; Hammersmith Functional Motor Scale; Outcome measures
1. Introduction
The advent of clinical trials in spinal muscular atrophy
(SMA) has highlighted the need to identify reliable outcome
measures and to collect natural history data [1,2]. A few studies
have already reported longitudinal data using different functional
measures [3–13] such as the Hammersmith Functional Motor
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Scale (HFMS). The HFMS, in its original version for
non-ambulant SMA patients or as an expanded version suitable
for both ambulant and non-ambulant SMA (HFMSE), is routinely
used in several centers across the world and it has also been
used for several multicenter natural history studies [6,7,9].
Recent studies in type 2 and 3 SMA patients have suggested
that the overall mean of HFMSE 12-month changes were minimal
[6] but there was no attempt to identify possible different
trajectories of progression in subgroups of patients. This
information may be valuable at the time of selecting inclusion
and stratification criteria for clinical trials or for the interpretation
of the results [14]. Even if the reported data include relatively
large cohorts it was felt that larger datasets were needed to
perform a more accurate analysis aimed at identifying possible
subgroups trajectories.
We retrospectively merged databases from different large
multicentric networks in the United States and Europe in order
to establish (i) 12-month HFMSE changes in a larger cohort
than those previously reported; (ii) possible differences of
progression between ambulant and non-ambulant patients; (iii)
the possible effect of different variables, such as gender,
baseline values or age on the progression of the disorder; and
(iv) possible outliers and the reasons for performing differently.
2. Subjects and methods
This retrospective study was performed by collecting data
from different existing large multicentric datasets, including
one network based in the United States (the Pediatric
Neuromuscular Clinical Research Network for SMA) and 5
European centers (three in Italy, one in UK and one in Belgium)
that are part of a larger European network.
All patients had a genetically confirmed diagnosis of SMA
with a homozygous deletion of exon7 in the SMN1 gene, and a
clinically confirmed diagnosis of type 2 or 3 SMA. To reduce
selection bias, all patients seen in the neuromuscular clinics
who fulfilled eligibility criteria were consecutively offered
enrollment. Only patients with at least two assessments at a
12-month interval were selected for this study. Patients in whom
one of the two performances was affected by transient pain,
fractures, recent pneumonia, or other infections, intercurrent
surgery, or any other factor that affected temporarily one of the
two assessments were excluded from the analysis. Similarly,
according to recent studies suggesting that the introduction of
albuterol may cause a sudden improvement in scores that can
persist for the first 12 months [15], we excluded those who had
started treatment in the 12 months before the study or who
started the treatment between the two assessments.
Clinical information regarding age and weight were noted.
Contractures were routinely assessed as part of clinical
evaluation but were not prospectively systematically assessed
using a standardized protocol. Baseline height, weight and
interval changes were identified in most subjects but not in a
systematic fashion.
As part of the activities of the two networks, all participants
or their guardians provided written informed consent approved
by the respective institutional review boards.
2.1. HFMSE
The scale consists of 33 items, investigating the child’s
ability to perform various activities. Each activity (item) is
scored on a 3-point scoring system, with a score of 2 for
“performs without modification”, 1 for “performs with
modification/adaptation” and 0 for “unable to perform”. A total
score can be achieved by summing the scores for all the
individual items. The total score can range from 0, if all the
activities are failed, to 66, if all the activities are achieved. All
items have to be tested without spinal jacket or orthoses.
2.2. Training sessions
Training was performed independently in US and Europe
networks. As part of the activity of each network, evaluators
used a procedure manual that was common for the two
networks, and were trained at in-person meetings. Inter and
intra observer reliability of the two networks have already been
reported [1,6,7].
2.3. Statistical analysis
The HFMSE was evaluated longitudinally over a 12-month
period of time. Summary statistics (N, mean, median, SD,
range) were used. Baseline values of the Hammersmith scale
were compared between ambulant and non-ambulant subjects
using an ANOVA model adjusting for age. The dependence of
the baseline values of the Hammersmith scale on age was
examined by an ANOVA model testing the heterogeneity
among age classes (since the relationship was not linear at a
visual inspection) and was compared between ambulant and
non-ambulant patients by an interaction test.
A piecewise linear regression was used to assess changes in
the slope of baseline values of the Hammersmith scale at
different cut points of age.
The 12-month change in the Hammersmith scale values was
compared between age classes by an analysis of variance,
adjusting for baseline in ambulant and non-ambulant patients.
As previous studies have shown that the great majority of
changes is within ±2 points, we considered this range of
changes [8,9]. The percentage of patients with a change <−2,
between −2 and 2, and >2 points was compared across age
classes by a Chi-square test (a multinomial model was used to
adjust for baseline values).
3. Results
A total of 294 patients fulfilled the inclusion criteria. Twenty
had transient issues affecting one of the two assessments (11
transient pain, 9 limited cooperation at one assessment).
Another 6 were excluded because they had started albuterol
within 6 months or after the first assessment.
The remaining 268 were included in the study for further
analysis. One hundred and forty-four of the 268 were males.
Their age ranged between 2.5 and 55.5 years at baseline (mean
10.65, SD 8.39). Sixty-eight were ambulant and 200 were non-
ambulant at the time of the assessment (196 type 2 and 4 type
3 who lost ambulation).
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The HFMSE scores ranged between 0 and 66 (mean 23.91,
SD 20.09) at baseline and between 0 and 66 at 12 months (mean
23.28, SD 20.07). The 12-month change was between −14 and
+9 (mean −0.56, SD 2.72) (Table 1).
Of the 268 patients, 206 (76.86%) had changes between −2
and +2 points, 41 (15.30%) had a decrease in scores of more
than 2 points and 21 (7.84%) had an increase in scores of more
than 2 points on the HFMSE (Fig. 1).
3.1. Ambulant versus non-ambulant
3.1.1. Baseline values
Baseline values of the HFMSE were significantly different
between ambulant and non-ambulant patients (Fig. 1): the mean
value was 53.6 (SD = 6.8) in ambulant and 13.8 (SD = 11.0) in
non-ambulant subjects (p < 0.001, adjusting for age).
The relationship between baseline values and age was
significantly different in ambulant and non-ambulant subjects
(p for age X ambulation interaction =0.007): there was no
association with age in ambulant subjects (Fig. 2), while there
was a significant heterogeneity at different age levels for non-
ambulant patients (p for association of baseline values with
different age groups <0.001).
Since the relationship clearly was not linear, with an increase
at younger age, and a subsequent decrease eventually reaching
a plateau, a stepwise regression was applied to test for the
presence of cut points of age, where the slope of the dependence
of Hammersmith values and age changes. Two relevant cut
points were detected: the slope was estimated to be 6.1
(SE = 3.1) points per year up to the age of 4.35 (first cut point,
SE = 0.48); followed by a slope of −7.2 points per year between
the age of 4.35 and the age of 15.2 (second cut point, SE = 3.4);
finally the slope after the age of 15.2 was 0.93 points per year
(Fig. 3). The greatest interval change was between 9–11 and
Table 1
Details of weight and contractures in outliers.
PZ Age SMA type 1 year weight gain Increase in contractures
1 3.6 II 5 kg No reported change
2 6.3 III A 5 kg No reported change
3 4.3 III A 7 kg No reported change
4 20.8 II 5 kg No reported change
5 7.1 II 7 kg No reported change
6 9.5 III A 13 kg No reported change
7 4.33 II 6 kg 10° ankles
8 5.4 II 6 kg No reported change
9 7.83 II 5 kg No reported change
10 12.10 III A 5 kg No reported change
11 10.70 III B 6 kg No reported change
12 16.83 II 7 kg No reported change
13 5 II 7 kg 15° knees
14 4.08 II 5 kg No reported change
15 9.70 III B 6 kg No reported change
16 6.7 III A 6 kg No reported change
17 8.25 II 6 kg No reported change
18 6 III A 1 kg 20° hips
19 10.5 III A No reported change 15° knees
20 14.7 III A No reported change 15° hips
21 3.5 II 1 kg 10° ankles
22 7 II 3 kg 15° knees
Fig. 1. HFMSE 12-month changes: individual details according to age.
Fig. 2. Baseline values of the Hammersmith scale according to age in ambulant
and non-ambulant children.
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11–13 years. There was no detectable difference in these
patterns between males and females.
According to these findings, in order to study the 12-month
change, we grouped patients in three different classes based on
their age: younger (age < 5 years), intermediate (age ≥ 5 and
age < 15 years) and older (age ≥ 15 years).
3.1.2. 12-month changes
The 12-month change was not significantly different between
ambulant and non-ambulant patients (average change = −0.56
in ambulant vs −0.57 in non-ambulant patients), but the difference
became significant when adjusting for baseline values and age
class (adjusted mean = +0.83 for ambulant patients vs −0.84
for non-ambulant patients, p = 0.029).
The 12-month change (adjusted for baseline) was not
associated with age in ambulant patients (p = 0.34), while it
differed significantly in different age groups in non-ambulant
patients: the mean 12-month change was +0.04 (SE = 0.34) in
the younger group, −0.96 (SE = 0.24) in the intermediate group
and −0.35 (SE = 0.43) in the older group (Fig. 4, p = 0.048). No
statistically significant differences were detectable for the sex of
the patients.
Separating ambulant children in 2 classes (SMA IIIA and
SMA IIIB) did not change the results. A trend for an increase of
change with age class was detectable in SMA IIIA children
(p = 0.067) while no association with age was revealed in SMA
IIIB patients (p = 0.80).
As an additional analysis, patients were classified according
to their 12-month change as those having a change ≤−2 points,
a change between −1 and +1 point, and ≥+2 points. There was
a different distribution of patients with these 3 levels of change
according to age class in non-ambulant patients (also after
adjusting for baseline levels) (Table S1).
4. Discussion
Our study provides the largest set of longitudinal data
reported so far in patients with SMA types 2 and 3. This was
obtained by merging smaller datasets including prospectively
collected data from different centers. Combining datasets was
possible because all the participating centers used the same
functional assessment with similar assessment schedules, and
had similar standards of care. Reliability across centers was
thought to be appropriate as not only all evaluators within the
individual networks received a formal training but evaluators
from different networks had the opportunity to share training
material and training procedures across networks. There were,
however, differences in the methods used for determining
contractures or scoliosis and in the additional information
collected, such as weight and height, that have limited the
possibility to explore the effect of some of these variables on
SMA progression.
The results obtained in 268 patients confirm previous
findings that ambulant and non-ambulant patients show small
mean changes over a 12-month period on the HFMSE. The
great majority of patients (over 75%) had changes ±2 points,
with less than 10% showing an improvement of more than 2
points, in agreement with previously reported data. We also
aimed to establish whether, given a much larger dataset, a
number of variables, such as functional level, gender or age
could affect the magnitude of changes. We were also interested
in establishing if any of these variables could provide some
explanation for the patients with changes falling outside ±2
point and, more generally, whether we could identify subgroups
of patients showing different trajectories of progression of the
disease.
When we analyzed the data subdividing the cohort into
ambulant and non-ambulant subgroups, there was a significant
difference both at baseline and on the 12-month changes
between the two subgroups.
Female patients tended to have better baseline values and
smaller changes compared to male patients in both ambulant
Fig. 3. Scatter of baseline values of the Hammersmith scale. Fig. 4. Average 12-month change of the Hammersmith scale according to age
classes and ambulation.
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and non-ambulant subgroups but the differences were not
significant at 12 months.
The relationship between baseline values and age, in
contrast, was different (p for age X ambulation interaction
=0.007) in the two subgroups as there was a significant
heterogeneity at different age levels for non-ambulant patients
(p for association of baseline values with different age groups
<0.001), but not for the ambulant ones. The profile observed at
baseline in the non-ambulant subgroup showed an increase at
younger age, with a subsequent decrease between the age of 5
and the age of 15 and a plateau in older patients.
A similar difference was observed also when 12-month
changes were analyzed. The 12-month change (adjusted for
baseline), again, was not associated with age in ambulant
patients (p = 0.34), but was significantly different in different
age groups in the non-ambulant ones. Patients between 5 and
15 years had the largest negative 12-month change (−0.96) as
opposed to smaller negative changes in the older group
(−0.35) and to a small positive mean change (+0.04) in the
youngest group. Not surprisingly, when we looked at the
outliers, the possibility of improving more than 2 points was
highest in the children below 5 years of age. These results are
in agreement with findings in previous clinical trials
evaluating phenylbutyrate, valproic acid, or salbutamol
[15–19] showing that children in this age range were more
likely to show motor functional improvement than the older
ones. This would also be in keeping with pathological data
derived from SMA-like mice suggesting that SMA
motoneuron death is a later postnatal phenomenon, preceded
by a severe chronic dying-back axonopathy [20].
In contrast, children between 5 and 15 years had the largest
negative 12-month change and the highest risk of losing more
than 2 points. This is likely to be due to the fact that in the years
leading to and throughout puberty, patients are more likely to
experience weight gain and increased contractures and
scoliosis. In our cohort, a sudden increase in weight or
contractures was reported in 22 of the outliers, while these
complications were not reported in the rest of the cohort.
However, as the study was not prospectively designed to capture
these aspects, and weight and height were not always
systematically noted at each assessment, we cannot rule out that
the annotation of these findings in the outliers was prompted by
the magnitude of changes observed and that similar findings
may also be occurring in patients with more stable scores.
These findings highlight the need to standardize a contracture
assessment protocol and systematically collect weight and
height and also adverse events using a standardized method.
The possible effect of increased weight and contractures are
concordant with previous observations regarding the decremental
effect of weight and BMI on functional activities [7,19,21] and
are also suggested by the fact that in older patients, in whom
contractures and weight are generally more stable, the scores
showed less changes. In this subgroup there were several patients
who had, in contrast, transient pain episodes that were not
included in the analysis. It is of note that altogether there were
approximately 10% of the patients in whom one of the two
performances was affected by intercurrent factors. This
information may be relevant at the time of powering new clinical
studies.
5. Conclusions
The overall results confirm that the mean 12-month changes
in the whole cohort were very small, but we were also able to
demonstrate that the range of individual changes was relatively
wide; and that although the majority of patients fell within ±2
points, there were a number of outliers including both patients
increasing or decreasing more than two points. Having a larger
cohort than those previously reported allowed us to identify
different profiles of progression in ambulant and non-ambulant
patients. Our data also suggest that age may play a more
important role in the progression of non-ambulant patients.
These findings will be of help when deciding inclusion and
stratification criteria for clinical trials. Further studies
collecting more detailed information on the changes in weight
and contractures, adverse events, and correlation with SMN2
copy number, that were not available for all the patients
included in the present study, will help to better define the effect
of these variables on the progression of SMA.
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